BioArctic's partner Eisai gets approval for Leqembi to treat Alzheimer's disease in Israel
BioArctic AB’s partner Eisai announced that Leqembi (generic name: lecanemab) has been approved for treatment of Alzheimer’s disease (AD) in Israel. Treatment with Leqembi should be initiated in patients with mild cognitive impairment (MCI) or mild …